Scarica l'app Stockscreener
10.52
1.03%
-0.13
Precedente Chiudi:
$10.65
Aprire:
$10.9
Volume 24 ore:
33,795
Relative Volume:
0.49
Capitalizzazione di mercato:
$141.62M
Reddito:
-
Utile/perdita netta:
$-8.89M
Rapporto P/E:
-15.03
EPS:
-0.7
Flusso di cassa netto:
$-6.48M
1 W Prestazione:
-6.56%
1M Prestazione:
-6.14%
6M Prestazione:
+6.90%
1 anno Prestazione:
-23.23%
Intervallo 1D:
$10.39
$11.02
Intervallo di 1 settimana:
$10.51
$11.49
Portata 52W:
$8.06
$15.47
Greenwich Lifesciences Inc Stock (GLSI) Company Profile
Nome
Greenwich Lifesciences Inc
Settore
Industria
Telefono
203-434-3290
Indirizzo
3992 BLUEBONNET DR, BUILDING 14, STAFFORD
Confronta GLSI con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GLSI
Greenwich Lifesciences Inc
|
10.39 | 145.16M | 0 | -8.89M | -6.48M | -0.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.81 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
472.68 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
552.20 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
809.14 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
331.45 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Greenwich Lifesciences Inc Stock (GLSI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-20 | Iniziato | Noble Capital Markets | Outperform |
| 2021-09-01 | Iniziato | H.C. Wainwright | Buy |
Greenwich Lifesciences Inc Borsa (GLSI) Ultime notizie
How hedge fund analytics apply to Greenwich LifeSciences Inc. stockTrade Analysis Report & Verified Swing Trading Watchlist - newser.com
What institutional flow reveals about Greenwich LifeSciences Inc.Quarterly Trade Review & Free Accurate Trade Setup Notifications - newser.com
What recovery options are there for Greenwich LifeSciences Inc.GDP Growth & Stock Portfolio Risk Control - newser.com
Why Greenwich LifeSciences Inc. stock is seen as undervalued2025 EndofYear Setup & Safe Entry Zone Tips - newser.com
Greenwich LifeSciences, Inc.Common stock (NQ: - FinancialContent
Is Greenwich LifeSciences Inc. building a consolidation basePortfolio Return Report & Low Volatility Stock Suggestions - newser.com
Can Greenwich LifeSciences Inc. stock hit analyst price targetsJuly 2025 Update & High Accuracy Trade Alerts - newser.com
Greenwich LifeSciences expands breast cancer trial to Austria By Investing.com - Investing.com Canada
Greenwich LifeSciences expands breast cancer trial to Austria - Investing.com India
What MACD and RSI say about Greenwich LifeSciences Inc.July 2025 Action & Verified Entry Point Detection - newser.com
Greenwich Lifesciences announces addition of Austria to FLAMINGO-01 clinical trial - MarketScreener
Greenwich LifeSciences Expands Phase III FLAMINGO-01 Clinical Trial to Austria - Quiver Quantitative
Greenwich LifeSciences Announces Addition of Austria to Flamingo-01 Clinical Trial - GlobeNewswire
Greenwich LifeSciences Inc. stock trendline breakdownMarket Growth Summary & Free Low Drawdown Momentum Trade Ideas - newser.com
Greenwich LifeSciences Inc. stock outlook for YEAR2025 Price Targets & Technical Pattern Based Buy Signals - newser.com
Published on: 2025-10-03 01:24:34 - newser.com
Greenwich LifeSciences expands breast cancer trial to Belgium By Investing.com - Investing.com Australia
Greenwich LifeSciences expands breast cancer trial to Belgium - Investing.com India
Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Trial to Belgium - The Manila Times
Greenwich LifeSciences Expands FLAMINGO-01 Clinical Trial to Belgium for Breast Cancer Immunotherapy Research - Quiver Quantitative
Major Breast Cancer Trial Expansion: Greenwich LifeSciences Adds Belgium to Global Phase III Study - Stock Titan
How to use a screener to detect Greenwich LifeSciences Inc. breakoutsMarket Growth Review & Step-by-Step Trade Execution Guides - newser.com
Greenwich LifeSciences Announces Addition of Portugal to Flamingo-01 Clinical Trial - Sahm
Greenwich LifeSciences expands breast cancer trial to Portugal By Investing.com - Investing.com Nigeria
Greenwich Lifesciences announces addition of Portugal to Flamingo-01 clinical trial - MarketScreener
Greenwich LifeSciences expands breast cancer trial to Portugal - Investing.com India
Greenwich LifeSciences Expands FLAMINGO-01 Clinical Trial to Portugal for Breast Cancer Immunotherapy - Quiver Quantitative
9,065 Annual Breast Cancer Cases: Greenwich LifeSciences Expands Critical Phase III Trial to Portugal - Stock Titan
What drives Greenwich LifeSciences Inc stock priceDouble Top/Bottom Patterns & Outperform With Our Smart Trading Calculator - earlytimes.in
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel's holdings dropped 12% in value as a result of the recent pullback - simplywall.st
HER2-Positive Breast Cancer Pipeline 2025: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Roche Pharma AG, Dizal Pharma, Greenwich LifeSciences, Ambrx - Barchart.com
Exit strategy if you’re trapped in Greenwich LifeSciences Inc.Market Trend Report & Growth-Oriented Investment Plans - newser.com
How to use Fibonacci retracement on Greenwich LifeSciences Inc.Weekly Gains Summary & Safe Capital Allocation Plans - newser.com
Greenwich LifeSciences expands breast cancer trial to Ireland - MSN
What analysts say about Greenwich LifeSciences Inc stockTrading Volume Surges & Low Cost Trading Ideas - earlytimes.in
Greenwich LifeSciences (NASDAQ:GLSI) Stock Price Down 0.2% – What’s Next? - Defense World
Greenwich Lifesciences Inc Azioni (GLSI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Greenwich Lifesciences Inc Azioni (GLSI) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Patel Snehal | CEO and CFO |
Apr 17 '25 |
Buy |
8.98 |
5,400 |
48,492 |
5,567,002 |
| Patel Snehal | CEO and CFO |
Apr 07 '25 |
Buy |
9.10 |
3,600 |
32,760 |
5,561,602 |
| Patel Snehal | CEO and CFO |
Apr 04 '25 |
Buy |
8.73 |
5,500 |
48,015 |
5,558,002 |
| Patel Snehal | CEO and CFO |
Jan 10 '25 |
Buy |
12.51 |
2,500 |
31,275 |
5,552,502 |
| Patel Snehal | CEO and CFO |
Jan 07 '25 |
Buy |
13.75 |
1,800 |
24,750 |
5,550,002 |
| Patel Snehal | CEO and CFO |
Jan 06 '25 |
Buy |
13.31 |
1,100 |
14,641 |
5,548,202 |
| Patel Snehal | CEO and CFO |
Jan 03 '25 |
Buy |
12.95 |
3,400 |
44,030 |
5,547,102 |
| Patel Snehal | CEO and CFO |
Jan 02 '25 |
Buy |
11.97 |
2,000 |
23,940 |
5,543,702 |
| Patel Snehal | CEO and CFO |
Dec 31 '24 |
Buy |
11.36 |
2,400 |
27,264 |
5,541,702 |
| Patel Snehal | CEO and CFO |
Dec 30 '24 |
Buy |
11.12 |
3,200 |
35,584 |
5,539,302 |
1.10%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):